Two classical, broad-spectrum HDAC inhibitors, trichostatin A (TSA), a hydroxamic acid, and the small carboxylate molecule, valproic acid (VPA), increase acetylation of histone H3 in HD, thereby restoring levels of some of the dysregulated transcripts [16]–[17]. Here, HDAC9 is linked to Huntington disease.